Use of ceftaroline in complicated methicillin-resistant staphylococcus aureus bacteremia

Hadeel Zainah, Jose Antonio Vazquez

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Ceftaroline is a novel broad-spectrum cephalosporin approved in October 2010 by the Food and Drug Administration for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by different organisms, including methicillin-resistant Staphylococcus aureus. We report 2 cases where ceftaroline was used effectively to treat complicated methicillin-resistant S aureus bacteremia.

Original languageEnglish (US)
Pages (from-to)58-60
Number of pages3
JournalInfectious Diseases in Clinical Practice
Volume21
Issue number1
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Methicillin-Resistant Staphylococcus aureus
Bacteremia
Bacterial Pneumonia
Skin
Methicillin Resistance
United States Food and Drug Administration
Cephalosporins
Infection
T 91825

Keywords

  • bacteremia
  • ceftaroline
  • MRSA

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Use of ceftaroline in complicated methicillin-resistant staphylococcus aureus bacteremia. / Zainah, Hadeel; Vazquez, Jose Antonio.

In: Infectious Diseases in Clinical Practice, Vol. 21, No. 1, 01.01.2013, p. 58-60.

Research output: Contribution to journalArticle

@article{99d816e82493499c9a919a96eab93496,
title = "Use of ceftaroline in complicated methicillin-resistant staphylococcus aureus bacteremia",
abstract = "Ceftaroline is a novel broad-spectrum cephalosporin approved in October 2010 by the Food and Drug Administration for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by different organisms, including methicillin-resistant Staphylococcus aureus. We report 2 cases where ceftaroline was used effectively to treat complicated methicillin-resistant S aureus bacteremia.",
keywords = "bacteremia, ceftaroline, MRSA",
author = "Hadeel Zainah and Vazquez, {Jose Antonio}",
year = "2013",
month = "1",
day = "1",
doi = "10.1097/IPC.0b013e3182602205",
language = "English (US)",
volume = "21",
pages = "58--60",
journal = "Infectious Diseases in Clinical Practice",
issn = "1056-9103",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Use of ceftaroline in complicated methicillin-resistant staphylococcus aureus bacteremia

AU - Zainah, Hadeel

AU - Vazquez, Jose Antonio

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Ceftaroline is a novel broad-spectrum cephalosporin approved in October 2010 by the Food and Drug Administration for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by different organisms, including methicillin-resistant Staphylococcus aureus. We report 2 cases where ceftaroline was used effectively to treat complicated methicillin-resistant S aureus bacteremia.

AB - Ceftaroline is a novel broad-spectrum cephalosporin approved in October 2010 by the Food and Drug Administration for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by different organisms, including methicillin-resistant Staphylococcus aureus. We report 2 cases where ceftaroline was used effectively to treat complicated methicillin-resistant S aureus bacteremia.

KW - bacteremia

KW - ceftaroline

KW - MRSA

UR - http://www.scopus.com/inward/record.url?scp=84872062378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872062378&partnerID=8YFLogxK

U2 - 10.1097/IPC.0b013e3182602205

DO - 10.1097/IPC.0b013e3182602205

M3 - Article

AN - SCOPUS:84872062378

VL - 21

SP - 58

EP - 60

JO - Infectious Diseases in Clinical Practice

JF - Infectious Diseases in Clinical Practice

SN - 1056-9103

IS - 1

ER -